Comparative evaluation of ATB Fungus 2 and Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility.

ATB Fungus 2 and SensititreYeastOne are commercial methods for antifungal susceptibility testing of yeasts. The agreement between these two methods was assessed with a total of 133 Candida strains (60 Candida albicans, 18 Candida dubliniensis, 29 Candida glabrata, and 26 Candida krusei). MIC endpoints were established after 24 h of incubation at 36-/+1 degrees C by each method. Intra-laboratory reproducibility of both methods was excellent (=or>99%). Overall agreement between ATB Fungus 2 and Sensititre YeastOne 3 MICs (within 2 dilutions) was 91.2-97.7% for amphotericin B, 5-fluorocytosine and itraconazole, and 82.7% for fluconazole. The categorical agreement when ATB Fungus 2 results were compared to those by SensititreYeastOne 3 was 93.2-98.5% for 5-fluorocytosine and amphotericin B, but lower for the triazoles (72.9-75.9%). This easy to perform method could be an alternative for routine use in the clinical microbiology laboratory for susceptibility testing of common Candida spp.

Comparative evaluation of ATB Fungus 2 and Sensititre Yeast One panels for testing in vitro Candida antifungal susceptibility

ATB Fungus 2 y SensititreYeastOne son métodos comerciales para el estudiode la sensibilidad in vitro de levaduras a los antifúngicos. La concordanciaentre estos dos métodos fue evaluada con un total de 133 aislamientos deCandida (60 Candida albicans, 18 Candida dubliniensis, 29 Candida glabrata y26 Candida krusei). La lectura de las CMIs se realizó para cada métododespués de 24 h de incubación a 36 ± 1 ºC. La reproducibilidadintralaboratorio de ambos métodos fue excelente ( 99%). La concordanciaglobal entre las CMIs de ATB Fungus 2 y Sensititre YeastOne 3 (en un rango± 2 diluciones) fue de 91,2-97,7% para anfotericina B, 5-fluorocitosina eitraconazol, y 82,7% para fluconazol. La concordancia por categorías cuandolos resultados de ATB Fungus 2 fueron comparados con los deSensititreYeastOne 3 fue de 93,2-98,5% para 5-fluorocitosina y anfotericina B,pero más baja para los triazoles (72,9-75,9%). Este método sencillo de realizarpuede ser una alternativa para uso de rutina en el laboratorio de microbiologíaclínica en el estudio de la sensibilidad de Candida spp(AU)

ATB Fungus 2 and SensititreYeastOne are commercial methods for antifungalsusceptibility testing of yeasts. The agreement between these two methodswas assessed with a total of 133 Candida strains (60 Candida albicans,18 Candida dubliniensis, 29 Candida glabrata, and 26 Candida krusei).MIC endpoints were established after 24 h of incubation at 36 ± 1 ºC by eachmethod. Intra-laboratory reproducibility of both methods was excellent( 99%). Overall agreement between ATB Fungus 2 and Sensititre YeastOne 3MICs (within 2 dilutions) was 91.2-97.7% for amphotericin B, 5-fluorocytosineand itraconazole, and 82.7% for fluconazole. The categorical agreement whenATB Fungus 2 results were compared to those by SensititreYeastOne 3 was93.2-98.5% for 5-fluorocytosine and amphotericin B, but lower for the triazoles(72.9-75.9%). This easy to perform method could be an alternative for routineuse in the clinical microbiology laboratory for susceptibility testing of commonCandida spp(AU)

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.

OBJECTIVES: The in vitro antifungal activity of posaconazole was compared with that of fluconazole and amphotericin B. MATERIALS AND METHODS: A microdilution method (M27-A2) was used with 331 clinical yeast isolates. RESULTS: The geometric mean MICs of posaconazole, fluconazole and amphotericin B were 0.16, 0.91 and 0.15 mg/L, respectively. Posaconazole was markedly more active than fluconazole and was active against 9/11 fluconazole-resistant Candida albicans, and five Candida glabrata had an MIC of posaconazole of 16 mg/L. CONCLUSIONS: These data indicate that posaconazole is a potentially effective antifungal agent for the treatment of mycoses caused by yeasts.

Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P.

We compared the in vitro antifungal activity of amphotericin B lipid complex (ABLC) with that of itraconazole (ITZ) against 535 yeast strains and 173 opportunistic filamentous fungi by using a microdilution method (National Committee for Clinical Laboratory Standards M27-A and M38-P). The overall geometric mean MIC was 0.13 microg/ml and 0.177 microg/ml for ITZ and ABLC, respectively, and the MIC(50) was 0.125 microg/ml for both agents against yeast isolates. ITZ had a similar or slightly superior efficacy compared to ABLC when tested against Candida albicans, Candida parapsilosis, Cryptococcus neoformans, Candida krusei, Candida glabrata and Candida tropicalis. Effectiveness against C. glabrata was lower for ITZ (MIC(90) 2 microg/ml, and for ABLC, 0.5 microg/ml). For Aspergillus fumigatus, activity of ITZ was superior in comparison with ABLC (MIC(90) 1 and 16 microg/ml, respectively); MIC(90) for Aspergillus niger was 4 and 2 microg/ml for ABLC and ITZ, respectively. Scedosporium spp. showed a low susceptibility to both ABLC and ITZ. In conclusion, ABLC and ITZ are useful alternatives for the treatment of severe fungal infections. The selection of an antifungal agent should be made considering the toxicological and pharmacological properties and cost/benefit relationship and be supported by the susceptibility of the isolate.